TELI COM - Telithromycin in Children With Otitis Media
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a multinational, randomized (1:1), double-blind, double-dummy, comparative, 2- treatmentgroup study in children (age range: ≥6 months and <72 months [< 6 years of age]) with AOM.Subjects will be randomized to receive either telithromycin (50 mg/mL) oral suspension 25 mg/kgonce daily for 5 days or azithromycin (40 mg/mL) oral suspension (10 mg/kg once on Day 1, followed by 5 mg/kg once daily on Days 2-5, not to exceed 500 mg onDay 1 and 250 mg/day from Days 2 - 5. Matching placebo suspensions for telithromycin and azithromycin will also be dispensed to provide blinding for the different treatment regimens.Assessments and reporting of safety will be carried out at all visits.
| Condition | Intervention | Phase |
|---|---|---|
|
Otitis Media, Suppurative Otitis Media, Purulent |
Drug: Telithromycin Drug: Azithromycin |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Multinational, Randomized, Double-Blind, Double-Dummy, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 25mg/kg od Versus 5 Days Azithromycin 10 mg/kg od Followed by 5 mg/kg od for 4 Days, in Children With Acute Otitis Media |
- The primary efficacy variables will be time to symptom resolution (TSR) and clinical cure at theposttherapy/TOC Visit 3.
- Adverse events (AEs) reported by subjects, their parents/legally authorized representative, orobserved by the investigators will be recorded throughout the study.
| Estimated Enrollment: | 1500 |
| Study Start Date: | January 2006 |
| Study Completion Date: | July 2006 |
| Primary Completion Date: | July 2006 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 6 Months to 6 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Subjects meeting all of the following criteria will be considered for enrollment into the study:
- Subjects ≥6 months and <72 months (< 6 years) of age;
- Recent (within the last 72 hours) and rapid onset of AOM symptoms and signs;
- The presence of MEF on otoscopy indicated by a bulging tympanic membrane;
- Otalgia or ear tugging or touching within the last 24 hours that interferes with or precludes normal activity or sleep;
- At least 1 of the following clinical findings not specific to AOM: fever, vomiting, diarrhea, anorexia, sleep disturbance, or irritability;
- Caregiver-reported AOM symptoms sufficient for entry according to protocol criteria.
- Caregiver-reported AOM symptoms diary
Tympanometry exhibiting:
- Type B curve or positive pressure peak curves.
Exclusion Criteria:
Subjects presenting with any of the following will not be included in the study:
- Uncertain diagnosis of AOM or mild to moderate symptoms and signs of AOM that would make the subject a candidate for observation and analgesic therapy with observation for 2-3 days.
- Otorrhea or tympanostomy tube present in the ear to be evaluated;
- Otitis externa;
- Down syndrome, cleft palate, craniofacial disorders, cystic fibrosis/mucoviscidosis, immotile cilia syndrome, congenital immunodeficiency or acquired immunodeficiency syndrome with <25% CD4 count or requiring prophylaxis for Pneumocystis jiroveci (carinii) or requiring treatment for an opportunistic infection;
- Known congenital long QT syndrome;
- Known or suspected uncorrected hypokalemia (≤3 mmol/L [mEq/L]), hypomagnesemia, bradycardia (<50 bpm);
- Myasthenia gravis;
- Known impaired renal function, as shown by creatinine clearance ≤25 mL/min;
- History of hypersensitivity or intolerance to macrolides or azithromycin;
- Previous enrollment in this study or previous treatment with telithromycin;
- Children of the investigator or subinvestigator, research assistant, pharmacist, study coordinator, other staff, or relative thereof directly involved in the conduct of the protocol.
Contacts and Locations| United States, New Jersey | |
| Sanofi-Aventis | |
| Bridgewater, New Jersey, United States, 08807 | |
| Argentina | |
| Sanofi-Aventis | |
| Buenos Aires, Argentina, 1642 | |
| Brazil | |
| Sanofi-Aventis | |
| Sao Paulo, Brazil, 05677-000 | |
| Canada | |
| Sanofi-Aventis | |
| Laval, Canada | |
| Chile | |
| Sanofi-Aventis | |
| Providencia, Santiago, Chile | |
| Colombia | |
| Sanofi-Aventis | |
| Santafe de Bogota, Colombia | |
| Costa Rica | |
| Sanofi-Aventis | |
| San José, Costa Rica | |
| Czech Republic | |
| Sanofi-Aventis | |
| Praha, Czech Republic, 160 00 | |
| Dominican Republic | |
| Sanofi-Aventis | |
| Santo-Domingo, Dominican Republic | |
| Guatemala | |
| Sanofi-Aventis | |
| Guatemala, Guatemala | |
| Israel | |
| Sanofi-Aventis | |
| Israel, Israel | |
| Panama | |
| Sanofi-Aventis | |
| Panama, Panama | |
| Peru | |
| Sanofi-Aventis | |
| Lima, Peru | |
| Study Director: | ICD CSD | Sanofi |
More Information
No publications provided
| Responsible Party: | ICD Study Director, sanofi-aventis |
| ClinicalTrials.gov Identifier: | NCT00315003 History of Changes |
| Other Study ID Numbers: | EFC6132, HMR3647B/3002 |
| Study First Received: | April 13, 2006 |
| Last Updated: | April 2, 2009 |
| Health Authority: | United States: Food and Drug Administration Canada: Ethics Review Committee Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica Chile: Instituto de Salud Publica de Chile Peru: General Directorate of Pharmaceuticals, Devices, and Drugs |
Keywords provided by Sanofi:
|
Otitis Media Suppurative Purulent Ketolide |
Azithromycin Telithromycin Controlled Clinical Trials |
Additional relevant MeSH terms:
|
Otitis Otitis Media Otitis Media, Suppurative Suppuration Ear Diseases Otorhinolaryngologic Diseases Infection Inflammation |
Pathologic Processes Azithromycin Telithromycin Anti-Bacterial Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 16, 2013